PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer
DOI: 10.1055/s-0043-1773793
Original Article

Successful Treatment of Recurrent Unresectable Oral Cancer with Sequential Targeted Therapy, Surgery, and Metronomic Chemotherapy

Diksha Dinker
1   Department of Surgical Oncology, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India
,
Ananth Pai
2   Department of Medical Oncology, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India
,
Keshava Rajan
1   Department of Surgical Oncology, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India
,
Naveena A.N. Kumar 
1   Department of Surgical Oncology, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Zoom Image
Naveena A.N. Kumar

A high incidence of locoregional recurrences in oral cavity cancers remains the biggest challenge leading to treatment failures post-surgery and radiotherapy. Our case report elaborates on one such recurrence pattern and the juxtaposition of various modalities applied to successfully not only eradicate the tumor but also to keep the recurrence at bay.

Keywords

unresectable oral cancer - OMCT - targeted therapy - head and neck squamous cell carcinoma - recurrence


Publikationsverlauf

Artikel online veröffentlicht:
31. August 2023

© 2023. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA. Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol 2012; 3: 149
    CrossrefPubMedSuche in Google Scholar
  • 2 Fan S, Tang QL, Lin YJ. et al. A review of clinical and histological parameters associated with contralateral neck metastases in oral squamous cell carcinoma. Int J Oral Sci 2011; 3 (04) 180-191
    CrossrefPubMedSuche in Google Scholar
  • 3 Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994; 73 (01) 187-190
    CrossrefPubMedSuche in Google Scholar
  • 4 Carvalho AL, Kowalski LP, Agra IM, Pontes E, Campos OD, Pellizzon AC. Treatment results on advanced neck metastasis (N3) from head and neck squamous carcinoma. Otolaryngol Head Neck Surg 2005; 132 (06) 862-868
    CrossrefPubMedSuche in Google Scholar
  • 5 Agra IM, Filho JG, Martins EP, Kowalski LP. Second salvage surgery for re-recurrent oral cavity and oropharynx carcinoma. Head Neck 2010; 32 (08) 997-1002
    CrossrefPubMedSuche in Google Scholar
  • 6 Kowalski LP, Carvalho AL, Martins Priante AV, Magrin J. Predictive factors for distant metastasis from oral and oropharyngeal squamous cell carcinoma. Oral Oncol 2005; 41 (05) 534-541
    CrossrefPubMedSuche in Google Scholar
  • 7 Forastiere AA, Shank D, Neuberg D, Taylor IV SG, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998; 82 (11) 2270-2274
    CrossrefPubMedSuche in Google Scholar
  • 8 Burtness B, Harrington KJ, Greil R. et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394 (10212): 1915-1928
    CrossrefPubMedSuche in Google Scholar
  • 9 Vermorken JB, Remenar E, van Herpen C. et al; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357 (17) 1695-1704
    CrossrefPubMedSuche in Google Scholar
  • 10 Posner MR, Hershock DM, Blajman CR. et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357 (17) 1705-1715
    CrossrefPubMedSuche in Google Scholar
  • 11 Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010; 7 (08) 455-465
    CrossrefPubMedSuche in Google Scholar
  • 12 Vermorken JB, Trigo J, Hitt R. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25 (16) 2171-2177
    CrossrefPubMedSuche in Google Scholar
  • 13 Glück S, Lau H, Mackinnon J, Syme R, Glück D. Metronomic therapy in recurrent and metastatic chemoresistant SCCHN: data from a pilot study. Biomed Pharmacother 2005; (59) S319
    CrossrefSuche in Google Scholar
  • 14 Patil V, Noronha V, Dhumal SB. et al. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health 2020; 8 (09) e1213-e1222
    CrossrefPubMedSuche in Google Scholar
  • 15 Pandey A, Desai A, Ostwal V. et al. Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: a retrospective study from rural India. South Asian J Cancer 2016; 5 (02) 52-55
    Thieme ConnectPubMedSuche in Google Scholar
  • 16 Pai PS, Vaidya AD, Prabhash K, Banavali SD. Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: a matched-pair analysis. Indian J Cancer 2013; 50 (02) 135-141
    CrossrefPubMedSuche in Google Scholar
  • 17 Tahara M, Kiyota N, Yokota T. et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol 2018; 29 (04) 1004-1009
    CrossrefPubMedSuche in Google Scholar